Urine Calcium and Bone Mineral Density in Calcium Stone-Forming Patients Treated with Alendronate and Hydrochlorothiazide

Arrabal‐Martín, Miguel; González-Torres, Samuel; Cano-García, María del Carmen; Haro-Muñoz, Tomás de; Abad-Menor, Felix; Arrabal-Polo, Miguel Ángel; Cózar-Olmo, J.M.

doi:10.1159/000443484

Cited by 7 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After internalization, bisphosphonates inhibit osteoclasts, preventing them from bone resorption [49]. Many observational and experimental studies have shown a positive association between bisphosphonate use and BMD [50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68], and several important randomized trials should be highlighted. The Fracture Intervention Trial (FIT) was originated to investigate the effect of alendronate on the frequency of fractures in postmenopausal women with low bone mass, although they also investigated the effect on BMD and showed that alendronate increased BMD at several sites [60][61][62].…”

Section: Bisphosphonatesmentioning

confidence: 99%

“…Most studies involving thiazides and BMD were conducted in patients with kidney stones or in postmenopausal women, all showing a positive effect of thiazide diuretics on BMD [51,227,[245][246][247][248][249][250][251][252]. For example, a retrospective analysis including 299 kidney stone patients showed an increase in BMD after 1 year of treatment with hydrochlorothiazide [245], and similar results were found in a prospective study, but only after 2 years of treatment [51]. An increase in BMD and a decrease in bone turnover markers with thiazides was shown in an observational study of 636 post-menopausal women [247].…”

Section: Thiazide Diureticsmentioning

confidence: 99%

See 1 more Smart Citation

The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density

Burgh

Keyser

Zillikens

et al. 2021

Drugs

View full text Add to dashboard Cite

Section: Bisphosphonatesmentioning

confidence: 99%

Section: Thiazide Diureticsmentioning

confidence: 99%

The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density

Burgh

Keyser

Zillikens

et al. 2021

Drugs

View full text Add to dashboard Cite

“…84,85 Dietary recommendations for stone reduction including a low sodium and normal calcium diet have also been shown to improve BMD. 86 Thiazide diuretics also reduce urinary calcium levels, decrease stone recurrence, 867 improve BMD in stone formers 85,87,88 and reduce the risk of hip fractures. 89 In addition, alkali citrate therapy has a positive effect on both stone recurrence and bone health by reducing bone resorption and buffering acid production.…”

Section: Treatment Of Calcium Stone Formers With Either a Thiazide Di...mentioning

confidence: 99%

Update – 2022 Canadian Urological Association guideline: Evaluation and medical management of the kidney stone patient

Bhojani

Bjazevic

Wallace

et al. 2022

CUAJ

View full text Add to dashboard Cite

with a high risk of recurrent stone disease undergo metabolic evaluation by any physician. 9 81% of patients interviewed would prefer to take prophylactic medication than undergo another stone episode, and 92% of respondents preferred medication to undergoing surgery. 10 Although patients indicate they would be interested in using medication to prevent future stones, compliance studies suggest otherwise. Close to 50% of patients prescribed pharmacological prevention were non-compliant, especially those on potassium citrate. 11 This data stresses the importance of a comprehensive metabolic assessment with implementaiton of individualized prevention strategies. With directed therapy and proper patient education, patient compliance and therapeutic success may be optimized.The economic burden of recurrent stone disease is also significant. Estimates of direct costs for patient care and the indirect costs related to lost work time exceed $5 billion USD. 12,13 Given the rising rates of obesity and diabetes and their association with stone formation, the cost of managing stone disease is expected to increase to 1.24 billion dollars yearly in the US by 2030. 14 This guideline is an update of the 2016 document and aims to identify patients at heightened risk of stone recurrence, to outline the required investigations to assess these patients, and to provide contemporary advice on dietary and medical interventions of proven benefit in the Canadian context. This current guideline addresses the evaluation and medical prophylaxis of upper urinary tract stones and not bladder stones. Literature reviewThe updated content included in this document is based on a review of the English language literature. A PubMed search was conducted encompassing the period from January 1, 2015 to July 1, 2021 to include the following terms: "nephrolithiasis", "urolithiasis", "kidney stone", "renal stone", or "urinary stone". In total, 11,640 article titles were reviewed and 293 were identified as potentially relevant for inclusion in the literature assessment for this guideline update. Management recommendations were modified if needed based on the most current literature since the last guideline was published in 2016. Studies were evaluated and recommendations made based on Oxford levels of evidence and grades of recommendation as per the CUA Guidelines Committee's directive. 15

show abstract

“…Among various types of stones, calcium oxalate stones are the most common urinary tract stones [2]. Various factors, the most important of which are stone size and location, are considered in treating patients with urinary tract stones [3]. Patients are examined by obtaining their history and carrying out diagnostic radiology such as sonography.…”

Section: Introductionmentioning

confidence: 99%

Predictive Variables of Success in Extracorporeal Shock Wave Lithotripsy

Nazari¹,

Naghipour²

2017

Foc Sci

View full text Add to dashboard Cite

Introduction: Kidney stone is a prevalent disease, especially in desert and arid areas like Rafsanjan in Iran. Extracorporeal Shock Wave Lithotripsy (ESWL) is a non-invasive treatment of kidney stones that success rate of which depends on various factors. This study aimed at investigating predictive variables of success in ESWL in patients referred to the ESWL Unit of Moradi hospital (Rafsanjan, Kerman, Iran) in 2016. Methods: All patients referred to the ESWL unit in the hospital during a 6-month period in 2016 were included in this study. Demographic information, size, location, and orientation of stones were collected from interviews and sonography observations. Finally, the obtained data was investigated with the statistical Chi-square and logistic regression tests. Results: The male to female ratio in patients with kidney stones was almost 2:1, and the overall estimated rate of lithotripsy was 71.7%. There was no difference between the male and female patients in the success of lithotripsy and, in addition, stone location did not affect the rate of success. The only successful predictor of ESWL was stone size. The larger stones were more successful broken than smaller. Conclusions: Stone size plays an important role in the selection of treatment method. Breaking of larger stones is more successful in ESWL due to the greater absorption of ultrasonic energy emitted by the machine and because of the more accurate determination of their location.

show abstract

Urine Calcium and Bone Mineral Density in Calcium Stone-Forming Patients Treated with Alendronate and Hydrochlorothiazide

Cited by 7 publications

References 25 publications

The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density

The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density

Update – 2022 Canadian Urological Association guideline: Evaluation and medical management of the kidney stone patient

Predictive Variables of Success in Extracorporeal Shock Wave Lithotripsy

Contact Info

Product

Resources

About